Ocular Therapeutix (OCUL) Return on Equity (2014 - 2026)

Ocular Therapeutix has reported Return on Equity for 13 years, with the latest figure at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.01%, changed 0.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.0%, up from 0.01% in the prior quarter.
• The five-year high for Return on Equity was 0.0% in Q2 2024, with the low at 0.16% in Q3 2023.
• Average Return on Equity over 5 years is 0.03%, with a median of 0.01% recorded in 2025.
• Year-over-year, Return on Equity declined 15 bps in 2023 and rose 16 bps in 2024.
• Tracing OCUL's Return on Equity over 5 years: stood at 0.02% in 2022, then rose by 13 bps to 0.02% in 2023, then jumped by 73 bps to 0.0% in 2024, then declined by 17 bps to 0.01% in 2025, then gained by 19 bps to 0.0% in 2026.
• The last three Return on Equity figures came in at 0.0% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.

Peer Comparison